TAG:
diagnostic testing
UroCor, Inc.; Histology & AP.
UROCOR, INC. MATCHES THERAPEUTICS WITH DIAGNOSTICS With the recent signing of a co-promotion agreement with Zeneca Pharmaceuticals, UroCor, Inc. is positioned to offer therapeutics as a complement to its diagnostic testing. Based in Oklahoma City, UroCor is a fast-growing c…
Regional Tox Laboratory Shows Sustained Growth
CEO SUMMARY: Over a three-year period, this regional substance abuse laboratory has shown dramatic growth in revenue and operating profits. Strong leadership combined with good implementation skills fuel this lab’s success. HERE’S ANOTHER QUIET SUCCESS story about a reg…
Niche Markets Boost Earnings For Both DIANON And LabOne
THIRD QUARTER EARNINGS at DIANON Systems and LabOne, Inc. demonstrate that niche market strategies can be growth engines for clinical laboratories, even in the face of declining reimbursement. As the crunch in clinical testing hit the laboratory industry in recent y…
Lab Industry Briefs
MONOLAYER PAP SMEAR TEST In travels to laboratories around the United States, THE DARK REPORT is getting interesting, but anecdotal, feedback about Cytyc Corp.’s ThinPrep® monolayer Pap smear test. Pathologists and laboratory directors are noticing two perceived benefits …
Joint Venture In Phoenix To Be Copied Elsewhere
CEO SUMMARY: Look for the Quest-Sonora joint venture to be followed by others in coming months. Competition and marketplace realities are forcing the three national laboratories to respond with groundbreaking strategies. Hospital laboratory partners in these deals can reap significant ben…
Future Laboratory Model Found In Oklahoma City
CEO SUMMARY: Even as commercial laboratories struggle to maintain financial solvency, Urocor displays phenomenal growth in specimen volume, market share and revenue during the last five years. It is no accident that this laboratory is succeeding. Urocor’s executives use sophisticated ma…
Management Philosophy Drives UroCor’s Success
CEO SUMMARY: In the year 1997, UroCor shows a financial strength and growth potential unlike most commercial laboratories. UroCor’s current success is a direct result of how UroCor’s management did things differently during the years from 1991 to the present. Much of UroCor’s succes…
National Labs Cut Costs Using Radical Strategies
CEO SUMMARY: All three national laboratories are dumping unprofitable accounts and unprofitable lines of testing. It ends the era when commercial labs “gave away” testing to any client willing to open an account. The three national laboratories are enacting stiffer requirements for ne…
National Lab Strategies Will Impact Competitors
CEO SUMMARY: Not since the era of commercial lab consolidation ended has such a significant trend emerged. As the three national labs eliminate service to unprofitable accounts, profound changes will occur to the market for laboratory and pathology services. How quickly this leads to impr…
CURRENT ISSUE
Volume XXXII, No. 13 – September 15, 2025
The Dark Report examines a new bill that would reform PAMA and avoid reimbursement rate cuts scheduled for January 2026. Clinical laboratory leaders are urged to make their voices heard in Congress. Also, an expert describes how labs can fix pre-analytical errors and avoid disaster.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.